CMOs Join Pharma Facility Swap Meet - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CMOs Join Pharma Facility Swap Meet
Contract manufacturers slim down to improve profitability.


Pharmaceutical Technology


Small-molecule active pharmaceutical ingredient (API) facilities are proving to be especially difficult to sell, except for those with high-containment capabilities. Wiederseim estimates that there are more than 500,000 gall. of chemical API capacity for sale in North America and nearly 1 million gall. worldwide.

Several factors are driving the sell-off of pharmaceutical chemical facilities, including the decline of legacy products, the shift of production to tax-favored countries such as Ireland and Singapore (at the expense of other European countries and Puerto Rico), and the increase in sourcing from India and China. Also, the trend toward high-potency APIs means that companies need far less production capacity for a given volume of finished-product sales.

Wiederseim says that there are far more sellers than buyers of pharmaceutical facilities, so the market is likely to remain weak. One of the best options for pharmaceutical companies seeking to sell properties is to find a buyer interested in converting the site to another use besides developing or manufacturing pharmaceuticals.

Some recent examples include Pfizer's (New York) manufacturing facility in Augusta, Georgia, which has been converted into an ethanol plant; Bayer (Leverkusen, Germany) site in West Haven, Connecticut, which has been bought by Yale University as a research campus; and the former Pfizer site in Skokie, Illinois, which Forest City Enterprises will convert into a bioscience incubator.

While CMOs have been eager buyers of pharmaceutical facilities in the past, we expect few, if any, of them to be buyers today. Ten years of experience in tinkering with their business model has taught CMOs several valuable lessons about the dangers of facility acquisitions, among them:

1. Having a few highly-used facilities is more likely to lead to success than having a lot of half-used facilities, no matter how cheaply they can be bought

2. In an industry where the cycle for negotiating a contract and starting production is three years or more, a 3–5 year contract for legacy products isn't really much of a head start

3. Borrowing money to buy facilities can lead to disastrous results [just ask Inyx (New York), which recently was put into receivership over loans taken to finance facility acquisitions].

Reflecting these lessons, CMOs have shown strong discipline of late. For instance, we know a number of CMOs would love to have an injectables manufacturing facility in North America, but none have taken a serious run at any of the facilities on the market. They aren't willing to inherit the problems of some of these facilities, and aren't ready to pay a steep price for the newer sites.

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905,
, http://www.pharmsource.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here